Drugs / AD 452
AD 452
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00931697 | Jun → Nov 2009 | — | Treague Ltd | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT00141934 | Aug 2005 → ? | rheumatoid arthritis | Sosei | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2010-01-06 | Nxera Pharma UK Limited | Results Other nxera.life ↗ |
| 2006-11-21 | Nxera Pharma UK Limited | Results Other nxera.life ↗ |
| 2006-11-21 | Nxera Pharma UK Limited | Results Sosei Announces Results of AD 452 Phase IIb Clinical Trial nxera.life ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2010-01-06 | Nxera Pharma UK Limited | Other nxera.life ↗ |
| 2006-11-21 | Nxera Pharma UK Limited | Other nxera.life ↗ |
| 2006-11-21 | Nxera Pharma UK Limited | Sosei Announces Results of AD 452 Phase IIb Clinical Trial nxera.life ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD 452 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00141934 ↗ |
| Known as | (+)-Mefloquine | “A Phase I Randomised, Double-Blind Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine” NCT00931697 ↗ |
| Known as | AD 452 (+) mefloquine | “A Phase I Randomised, Double-Blind Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine” NCT00931697 ↗ |